Riikka Räty

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

Christian Winther Eskelund, Christina Dahl, Jakob Werner Hansen et al. · Blood · 2017 · 383 citations · Full text

Nordic <scp>MCL</scp>2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by <scp>BEAM</scp> or <scp>BEAC</scp> + autologous stem‐cell support: still very long survival but late relapses do occur

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · British Journal of Haematology · 2012 · 265 citations

Cell Therapy, Immunology, Pathology +22

15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (<scp>MCL</scp>2): prolonged remissions without survival plateau

Christian Winther Eskelund, Arne Kolstad, Mats Jerkeman et al. · British Journal of Haematology · 2016 · 207 citations · Full text

Immunology, Pathology, Hematological Malignancy +16

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Christian H. Geisler, Arne Kolstad, Anna Laurell et al. · Blood · 2009 · 184 citations

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Disha Malani, Ashwini Kumar, Oscar Brück et al. · Cancer Discovery · 2021 · 182 citations · Full text